Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998285 | 0.88 | HTR6 (0.51) | HTR6BCHE | |
| SCHEMBL1997016 | 0.83 | HTR6 (0.55) | HTR6POLBL3MBTL1MEN1KMT2A | |
| SCHEMBL1997952 | 0.82 | HTR6 (0.61) | HTR6MTNR1AMTNR1BPOLBL3MBTL1 | |
| SCHEMBL20840619 | 0.82 | HTR6 (0.68) | HTR6POLBL3MBTL1MEN1KMT2A | |
| SCHEMBL1994427 | 0.80 | HTR6 (0.56) | HTR6POLBL3MBTL1MEN1KMT2A | |
| SCHEMBL1996422 | 0.76 | HTR6 (0.62) | HTR6POLBL3MBTL1MEN1KMT2A | |
| SCHEMBL27751256 | 0.73 | HTR6 (0.62) | HTR6POLBL3MBTL1MEN1KMT2A | |
| SCHEMBL1993693 | 0.72 | HTR6 (0.57) | HTR6POLBL3MBTL1MEN1KMT2A | |
| SCHEMBL2001812 | 0.70 | HTR6 (0.48) | HTR6POLBL3MBTL1MEN1KMT2A | |
| SCHEMBL6195294 | 0.70 | MTNR1A (1.00) | MTNR1AMTNR1BL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960374-B2 | e.g. 2,5-methylene-9-(phenylsulfonyl)-1,2,3,4,5,9-hexahydro[1,5]oxazocino[3,2-e]indole; serotonin receptors antagonist or partial agonist; metabolic diseases, e.g. obesity, insulin resisitance, type 2 diabetes, eating disorders; antidepressant, anxiolytic agent; cosmetics | PROXIMAGEN LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-20080176829-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176829-A1 | Compounds | HTR6, HTR1B, HTR1A | HTR6 1/4885MTNR1A 45/4885MTNR1B 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.